BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 15670587)

  • 21. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors.
    Chang WP; Koelsch G; Wong S; Downs D; Da H; Weerasena V; Gordon B; Devasamudram T; Bilcer G; Ghosh AK; Tang J
    J Neurochem; 2004 Jun; 89(6):1409-16. PubMed ID: 15189343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
    Lahiri DK; Chen D; Maloney B; Holloway HW; Yu QS; Utsuki T; Giordano T; Sambamurti K; Greig NH
    J Pharmacol Exp Ther; 2007 Jan; 320(1):386-96. PubMed ID: 17003227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic and pharmacological evidence of intraneuronal Abeta accumulation in APP transgenic mice.
    Philipson O; Lannfelt L; Nilsson LN
    FEBS Lett; 2009 Sep; 583(18):3021-6. PubMed ID: 19683527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
    Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
    J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
    Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
    J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brain.
    Goggi JL; Lewis HD; Mok J; Harrison T; Shearman MS; Atack JR; Best JD
    J Neurosci Methods; 2006 Oct; 157(2):246-52. PubMed ID: 16859750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.
    Refolo LM; Pappolla MA; LaFrancois J; Malester B; Schmidt SD; Thomas-Bryant T; Tint GS; Wang R; Mercken M; Petanceska SS; Duff KE
    Neurobiol Dis; 2001 Oct; 8(5):890-9. PubMed ID: 11592856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease.
    Hook V; Kindy M; Hook G
    Biol Chem; 2007 Feb; 388(2):247-52. PubMed ID: 17261088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
    Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides.
    McCarty MF
    Med Hypotheses; 2006; 67(4):682-97. PubMed ID: 16828233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice.
    Lanz TA; Himes CS; Pallante G; Adams L; Yamazaki S; Amore B; Merchant KM
    J Pharmacol Exp Ther; 2003 Jun; 305(3):864-71. PubMed ID: 12626636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.
    Lanz TA; Karmilowicz MJ; Wood KM; Pozdnyakov N; Du P; Piotrowski MA; Brown TM; Nolan CE; Richter KE; Finley JE; Fei Q; Ebbinghaus CF; Chen YL; Spracklin DK; Tate B; Geoghegan KF; Lau LF; Auperin DD; Schachter JB
    J Pharmacol Exp Ther; 2006 Nov; 319(2):924-33. PubMed ID: 16920992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease.
    Prasad CV; Zheng M; Vig S; Bergstrom C; Smith DW; Gao Q; Yeola S; Polson CT; Corsa JA; Guss VL; Loo A; Wang J; Sleczka BG; Dangler C; Robertson BJ; Hendrick JP; Roberts SB; Barten DM
    Bioorg Med Chem Lett; 2007 Jul; 17(14):4006-11. PubMed ID: 17502137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carbamate-appended N-alkylsulfonamides as inhibitors of gamma-secretase.
    Bergstrom CP; Sloan CP; Lau WY; Smith DW; Zheng M; Hansel SB; Polson CT; Corsa JA; Barten DM; Felsenstein KM; Roberts SB
    Bioorg Med Chem Lett; 2008 Jan; 18(2):464-8. PubMed ID: 18178084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.